Leo Pharma wins Japanese approval to launch and manufacture main asset
Japan Ministry of Health, Labor and Welfare has approved Leo Pharma’s launch of Adtralza (tralokinumab), a treatment for adults with atopic dermatitis, the Danish pharmaceutical firm announces in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma reaches endpoints in phase III hand eczema trial
For subscribers